12:00 AM
Jun 04, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Enzalutamide: Expanded access program started

Medivation and Astellas began an open-label, U.S. expanded access program to evaluate enzalutamide in CRPC patients previously treated with docetaxel. Late last month, Medivation submitted an NDA to...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >